Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 5/20 | 0.46 |
| ▸ | CDK2 | P24941 | 5/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.46 |
| ▸ | CCND1 | P24385 | 2/20 | 0.46 |
| ▸ | CDK7 | P50613 | 2/20 | 0.46 |
| ▸ | CCNH | P51946 | 2/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611372 | 0.86 | MAP4K1 (0.41) | CCNA2CDK2CDK1CDK4CCNB1 | |
| SCHEMBL16611763 | 0.83 | CCNA2 (0.43) | CCNA2CDK2CDK1CDK4CCNB1 | |
| SCHEMBL16610962 | 0.80 | MAP4K1 (0.41) | CCNA2CDK2CDK1CDK4CCNB1 | |
| SCHEMBL16611246 | 0.79 | CDK2 (0.44) | CCNA2CDK2CDK1CDK4CCNB1 | |
| SCHEMBL16611322 | 0.75 | TBK1 (0.43) | CCNA2CDK2CDK1CDK4CCNB1 | |
| SCHEMBL16610957 | 0.75 | LRRK2 (0.31) | LRRK2 | |
| SCHEMBL16610791 | 0.70 | KCNJ5 (0.36) | CCNA2CDK2 | |
| SCHEMBL16611115 | 0.70 | CCNA2 (0.41) | CCNA2CDK2CDK1CDK4CCNB1 | |
| SCHEMBL16611300 | 0.70 | KHK (0.46) | MAP4K1 | |
| SCHEMBL16611220 | 0.70 | PDGFRB (0.41) | CCNA2CDK2CDK1CDK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | CCNA2 1165/4885CDK2 302/4885CDK1 207/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | CCNA2 1165/4885CDK2 302/4885CDK1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.